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Abstract
Background: Japanese encephalitis (JE), caused by a mosquito-borne flavivirus, is endemic to the entire south-east Asian
and adjoining regions. Currently no therapeutic interventions are available for JE, thereby making it one of the most
dreaded encephalitides in the world. An effective way to counter the virus would be to inhibit viral replication by using anti-
sense molecules directed against the viral genome. Octaguanidinium dendrimer-conjugated Morpholino (or Vivo-
Morpholino) are uncharged anti-sense oligomers that can enter cells of living organisms by endocytosis and subsequently
escape from endosomes into the cytosol/nuclear compartment of cells. We hypothesize that Vivo-Morpholinos generated
against specific regions of 39 or 59 untranslated regions of JEV genome, when administered in an experimental model of JE,
will have significant antiviral and neuroprotective effect.
Methodology/Principal Findings: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of
Morpholinos (5 mg/kg body weight) daily for up to five treatments. Survivability of the animals was monitored for 15 days
(or until death) following which they were sacrificed and their brains were processed either for immunohistochemical
staining or protein extraction. Plaque assay and immunoblot analysis performed from brain homogenates showed reduced
viral load and viral protein expression, resulting in greater survival of infected animals. Neuroprotective effect was observed
by thionin staining of brain sections. Cytokine bead array showed reduction in the levels of proinflammatory cytokines in
brain following Morpholino treatment, which were elevated after infection. This corresponded to reduced microglial
activation in brain. Oxidative stress was reduced and certain stress-related signaling molecules were found to be positively
modulated following Morpholino treatment. In vitro studies also showed that there was decrease in infective viral particle
production following Morpholino treatment.
Conclusions/Significance: Administration of Vivo-Morpholino effectively resulted in increased survival of animals and
neuroprotection in a murine model of JE. Hence, these oligomers represent a potential antiviral agent that merits further
evaluation.
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Introduction
The genus Flavivirus is composed of more than 70 different
closely related species [1]. Many flaviviruses are arthropod-borne
and causes significant human diseases. Among these, the four
serotypes of dengue virus (DENV), yellow fever virus (YFV), West
Nile virus (WNV) and Japanese encephalitis virus (JEV) are
categorized as emerging global pathogens [2]. JEV is a mosquito-
borne, positive sense, single stranded RNA virus, responsible for
frequent epidemics of encephalitis, predominantly in children, in
most parts of Southeast Asia and adjoining regions. It is the causal
factor for 30,000–50,000 cases of encephalitis occurring every year
and accounts for about 10,000 deaths annually with serious
neurological squeal in the survivors [3]. JEV has been expanding
its ‘geographical footprint’ into previously non-endemic regions
and with several billion people at risk, Japanese encephalitis (JE)
represents an internationally emerging concern in tropical and
sub-tropical countries. Currently three types of JE vaccine are in
use- the inactivated mouse-brain derived, the inactivated cell-
culture derived and the live attenuated cell-culture derived.
However, there are limitations for their usage in terms of
availability, cost and safety [4]. At present, chemotherapy against
JEV is largely supportive and not targeted towards the virus. A lot
of avenues has been explored in the past and are also being
currently tried, so as to develop a safe and effective molecule that
would be able to prevent the virus from replicating within the host.
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The JEV genome is approximately 11 kb in length that carries a
single long open reading frame (ORF) flanked by a 95-neucleotide
59 untranslated region (59 UTR) and a 585-neucleotide 39 UTR.
The ORF encodes a polyprotein which is processed by viral and
cellular proteases into three structural and seven non structural
proteins [5,6]. The 59 and 39 UTRs of the JEV genome contain
conserved sequence elements and can form conserved stem loop
structure. 59 UTR contain secondary structures which are required
for the formation of translation pre-initiation complex [7]. JEV
requires long range RNA-RNA interaction between 59 and 39
regions of its genome for efficient replication; one such interaction
occurs between a pair of 10 complementary nucleotides, located in
coding sequence for the capsid protein at 136–146 nucleotides from
59 end of the genome, and 39 cyclization sequence, commonly
denoted as 39CSI (39 conserved sequence I) located at 104–114
nucleotides from 39 end of the genome [8,9]. The 39CSI is highly
conserved across members of JEV serocomplex, indicating the
possibility that RNA elements within the 59 and 39 UTRs in JEV
genome are essential for its replication.
Anti-sense oligonucleotides have been shown to be effectively
used as therapeutic agents against viral infection. In one such study
siRNA generated against the cd loop-coding sequence in domain
II of the viral Envelope protein (which is highly conserved among
all flaviviruses because of its essential role in membrane fusion) has
been found to protect against lethal encephalitis [10]. Similarly
siRNAs has also been generated against various nonstructural
proteins of JEV and were found to be effective in inhibiting viral
replication [11,12]. Anti-sense approach has also been employed
to inhibit flaviviral replication by generating anti-sense molecules
against RNA elements within the 59 and 39 UTRs in flaviviral
genome. In one such approach, DNAzyme against 39 UTR of JEV
genome has be found to be effective in controlling virus infection
in a murine model [13]. Under the same approach but with
different kind of anti-sense oligonuleuotide called Morpholino,
flaviviral replication has been inhibited in cultured cells as well as
in animal models [14,15].
Morpholino oligomers are single stranded DNA analogues
containing same nitrogenous bases as DNA but joined by
backbone consisting of morpholine rings and phosphorodiamidate
linkages [16]. For efficient delivery into cells these Morpholino are
often conjugated with arginine rich peptide [17]. However, in the
current study we have used a different type of Morpholino
oligomer called Vivo-Morpholino against 39CSI and one of the
secondary structures present in 59 UTR of the JEV genome. Vivo-
Morpholino are specialized type of non-peptide Morpholino
oligomers, conjugated with a new transport structure that provides
effective delivery into a wide variety of tissues in living animals,
thereby raising the possibilities of their use as therapeutic agents.
The transporter comprises of a dendritic structure assembled
around a triazine core which serves to position eight guanidinium
head groups in a conformation effective to penetrate cell
membranes. Vivo-Morpholinos have also been shown to effec-
tively enter and function within cultured cells [18]. Vivo-
Morpholinos are also cost effective, non immunogenic, and stable
under physiological conditions as compared to other types of
Morpholinos. This study was designed to evaluate whether the use
of Vivo-Morpholinos as therapeutic agents, is possible in an
experimental model of JE. We intend to show that these
specifically designed Vivo-Morpholinos are effective in countering
the viral load in the body, thereby imparting significant protection
to the animals that were infected with a lethal dose of JEV.
Materials and Methods
Ethics statement
All animal experiments were approved by the institutional
animal ethical review board named ‘‘Institutional Animal and
Ethics Committee of National Brain Research Centre’’. The
animal experiment protocol approval no. is NBRC/IAEC/2007/
36. Animals were handled in strict accordance with good animal
practice as defined by Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), Ministry of
Environment and Forestry, Government of India.
Virus and cells
Vero cells (a kind gift from Dr. Guruprasad Medigeshi,
Translational Health Science and Technology Institute, Gurgaon,
India) and Neuro2A (obtained from National Centre for Cell
Science, Pune, India) cells were grown in DMEM (Dulbecco’s
modified Eagles medium, supplemented with 10% fetal bovine
serum (FBS) and antibiotics. The GP78 strain of JEV was
propagated in suckling BALB/c mice and their brains were
harvested when symptoms of sickness were observed. A 10% tissue
suspension was made in MEM (minimum essential medium),
followed by centrifugation at 10,0006g and finally filtered through
a 0.22 m sterile filter [19]. JEV was titrated by plaque formation on
Vero cell monolayer. Vero cells were seeded in six-well plates to
form semi-confluent monolayer in about 18 h. Cell monolayer were
inoculated with 10-fold serial dilutions of virus samples made in
MEM containing 1% FBS and incubated for 1 h at 37uC with
occasional shaking. The inoculum was removed by aspiration and
the monolayers were overlaid with MEM containing 4% FBS, 1%
low-melting-point agarose and a cocktail of antibiotic–antimycotic
solution (Gibco, Invitrogen Corporation, Grassland, NY, USA)
containing penicillin, streptomycin, and amphotericin B. Plates
were incubated at 37uC for 72–96 h until plaques became visible.
To allow counting of the plaques, the cell monolayer was stained
with crystal violet after fixing the cells with 10% formaldehyde.
Morpholino oligonucleotides
All Vivo-Morpholino (MO) oligos were commercially procured
from Gene Tools LLC, (Philomath, OR, USA). MOs were
Author Summary
Japanese encephalitis (JE) is caused by a flavivirus that is
transmitted to humans by mosquitoes belonging to the
Culex sp. The threat of JE looms over a vast geographical
realm, encompassing approximately 10 billion people. The
disease is feared because currently there are no specific
antiviral drugs available. There have been reports where
other investigators have shown that agents that block viral
replication can be used as effective therapeutic counter-
measures. Vivo-Morpholinos (MOs) are synthetically pro-
duced analogs of DNA or RNA that can be modified to
bind with specific targeted regions in a genome. In this
study the authors propose that in an animal model of JE,
MOs specifically designed to bind with specific region of JE
virus (JEV) genome, blocks virus production in cells of
living organisms. This results in reduced mortality of
infected animals. As the major target of JEV is the nerve
cells, analysis of brain of experimental animals, post
treatment with MOs, showed neuroprotection. Studies in
cultured cells were also supportive of the antiviral role of
the MOs. The potent anti-sense effect in animals and lack
of obvious toxicity at the effective dosage make these MOs
good research reagents with future therapeutic applica-
tions in JE.
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designed to be complementary to sequences in the JEV (GP78
strain) genome, as shown in Table 1. These oligonucleotides
targeted specific regions in the 39 and 59 UTRs of the JEV
genomic RNA (Figure 1). A 21 base scrambled MO of random
sequence (SC-MO) was used as a negative control in all the
experiments. All MO sequences were screened with BLAST
(http://www.ncbi.nlm.nih.gov/BLAST) against primate and mu-
rine mRNA sequences and the SC-MO was additionally screened
against all flaviviral sequences. All MOs were procured in 300
nanomole quantities as a liquid of 0.5 mM stock (approximately
4 mg/mL) in buffered saline. They were diluted with sterile 16
PBS to achieve desired concentrations, and stored at 4uC as
aliquots.
Animal model and treatment schedule
Five to six weeks old BALB/c mice of either sex were randomly
distributed into 5 groups- Sham, JEV-infected, JEV-infected and
treated with scrambled Morpholino (JEV+SC-MO), JEV-infected
and treated with Morpholino against viral 39 conserved region
(JEV+39 MO) and JEV-infected and treated with Morpholino
against secondary structure in the 59UTR of viral RNA (JEV+59
MO). Initially each group contained 8 animals. Animals belonging
to all groups except Sham were infected with 36105 plaque
forming units (PFU) of JEV (GP78 strain) and that day was
considered as day zero [20]. Animals of Sham group received
equal volume of filtered MEM. Starting from 3 h post infection on
day zero, 100 mg of SC-MO, 39 MO and 59 MO, diluted in
0.1 mL of sterile 16PBS (corresponding to 5 mg/kg body weight),
were administered to animals belonging to JEV+SC-MO, JEV+39
MO and JEV+59 MO groups respectively, once per day, for 5
consecutive days. Animals belonging to the Sham-treatment group
received equal volumes of sterile 16 PBS only. Survivality of
animals in each group following JEV infection and Morpholino
treatment were monitored daily upto 15 days post JEV infection
(or till their death, whichever was earlier). Toxicity of the
Morpholinos in mice was evaluated by weight loss and abnormal
behavioral & clinical observations (including tremors, ruffled fur,
hunching, ataxia, gait abnormalities), in a masked manner to
minimize bias [14,20].
Cytokine bead array
Mouse cytokine bead array (CBA) kits were used to quantita-
tively measure cytokine levels in mouse whole-brain lysates. 50 mL
of bead mix containing a population of beads with distinct
fluorescence intensities that have been coated with capture
antibodies for different cytokines, and 50 mL of whole-brain
lysates were incubated together, along with equal volume of
phycoerythrin (PE)-conjugated detection antibodies, for 2 h at
room temperature, in dark. The beads were then washed and re-
suspended in 300 mL of supplied 16wash buffer. The beads were
acquired using Cell Quest Pro Software in FACS Calibur and
analyzed using BD CBA software (Becton Dickinson, San Diego,
CA). Standard curve was prepared by incubating 50 mL of
supplied mouse inflammation standards with 50 mL of bead mix
and PE-conjugated detection antibodies [21].
Immunoblotting
Protein concentrations of whole brain lysates were estimated by
Bradford method. Sample volumes containing 20 mg of protein
were electrophoresed on polyacrylamide gel and transferred onto
nitrocellulose membrane. After blocking with 7% skimmed milk,
the blots were incubated overnight at 4uC with primary antibodies
against JEV E-glycoprotein (Abcam, USA), and JEV NS5 (a kind
gift from Dr. Chun-Jung Chen, Taichung Veterans General
Hospital, Taichung, Taiwan), iNOS (Upstate-Chemicon, USA),
HSP-70, SOD-1 (Santa Cruz Biotechnology, CA, USA), TRX
(AB Frontiers, Korea; a kind gift from Dr. Ellora Sen, NBRC),
phospho NFkB, phospho ERK1/2, total ERK1/2 and phos-
phoP38 MAP kinase (Cell Signaling, USA) at 1:1000 dilutions.
After extensive washes with PBS–Tween, blots were incubated
with appropriate secondary antibodies conjugated with peroxidase
(Vector Laboratories, CA, USA). The blots were again washed
with PBS–Tween and processed for development using chemilu-
minescence reagent (Millipore, USA). The images were captured
and analyzed using Chemigenius, Bioimaging System (Syngene,
Cambridge, UK). The blots were stripped and reprobed with anti-
b-tubulin (Santa Cruz Biotechnology, USA) to determine
equivalent loading of samples [22].
Immunohistochemistry
For immunohistochemical staining, brains from scarified
animals were excised following repeated transcardial perfusion
with ice-cold saline and fixed with 4% paraformaldehyde. Twenty
micron thick cryosections were made with the help of Leica
CM3050S cryostat and processed for immunohistochemical
staining to detect presence of JEV antigen in the brain and to
label activated microglia. Sections were incubated overnight at
4uC with mouse anti-JEV antigen (Nakayama, 1:250) (Chemicon,
CA, USA) and rabbit anti-Iba-1 (1: 500; Wako, Osaka, Japan),
respectively. After washes, slides were incubated with FITC-
conjugated anti-mouse or anti-rabbit secondary antibodies (Vector
laboratories Inc. Burlingame, USA) and following final washes,
sections were sections were cover slipped after mounting with 49-6-
diamidino-2-phenylindole (DAPI, Vector laboratories Inc.). The
slides were observed under Zeiss Axioplan 2 fluorescence
microscope and Zeiss Apotome microscope (Zeiss, Gottingen,
Germany), respectively [21].
Thionin staining
Cryosections of brain from Sham-treated, JEV-infected and
JEV-infected and MO treated animals were rinsed in de-ionized
water followed by incubation with the thionin dye. The excess dye
Table 1. Names, sequences and target locations of used Vivo-Morpholinos.
Morpholino name
Morpholino sequence
(59-39)
Targeted nucleotides in the JEV genome
(GenBank: AF075723.1)
39 MO TCC CAG GTG TCA ATA TGC TCT T 10861–10882
59 MO AAG CCA AGA AGT TCA CAC AGA T 9–22
SC-MO ACT CCA TCG TTC AGC CTC TGA NA
NA- Not applicable.
doi:10.1371/journal.pntd.0000892.t001
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was washed off and the slides were immersed in alcohol-dioxane
(1:1) solution for differentiation. After two changes in xylene the
slides were mounted with DPX and observed under a Leica 4000
DB light microscope (Leica Microsystems, USA) [23].
Reactive oxygen species (ROS) assay
The level of ROS produced within brain tissue of each
treatment groups were measured by the cell permeable, non-
polar, H2O2-sensitive probe 5(and 6)-chlromethyl-20,70-dichlor-
odihydrofluoresceindiacetate (CM-H2DCFDA; Sigma, USA).
CM-H2DCFDA diffuses into cells, where its acetate groups are
cleaved by intracellular esterases, releasing the corresponding
dichlorodihydrofluorescein derivative. Subsequent oxidations of
CM-H2DCFDA yields a fluorescent adduct dichlorofluorescein
that is trapped inside the cell. Brain homogenates were treated
with 5 mM solution of CM-H2DCFDA followed by incubation in
dark at room temperature for 45 min and then the relative
fluorescence intensity were measured with the help of Varioskan
Flash multimode reader (Thermo Electron, Finland) at excitation
500 nm and emission 530 nm. The fluorescence intensity of
intracellular CM-H2DCFDA is a linear indicator of the amount of
H2O2 in the cells. The measured mean fluorescence intensity was
then normalized to equal concentrations of protein in each sample
[23].
Nitric oxide (NO) assay
Nitric oxide released from brain homogenates following MO
treatment was assessed using Griess reagent as described
previously. Briefly, 100 mL of Griess reagent (Sigma, St. Louis,
USA) was added to 100 mL of brain homogenate and incubated in
dark for 15 min. The intensity of the color developed was
estimated at 540 nm with the help of a Benchmark plus 96-well
ELISA plate reader (Biorad, CA, USA). The amount of nitrite
accumulated was calculated (in mM) from a standard curve
constructed with different concentrations of sodium nitrite [21].
Intracellular staining by flow cytometry for JEV antigen
Mouse neuroblastoma cells (N2a) were plated in five 60 mm
plates at a density of 56105 cells/plate, and were cultured for
18 h. After 6 h in serum free DMEM, cells were either mock-
Figure 1. Regions of the JEV (GP78 strain) genome that are blocked by the MOs. Schematic diagram showing the secondary structure of
the 39 and 59 UTR of JEV genomic RNA as predicted by the Mfold program [41]. The regions blocked by the 39 MO and 59 MO are marked by black
curved lines and marked with arrows. Numbers in the smaller font refer to the nucleotide position of the JEV genome.
doi:10.1371/journal.pntd.0000892.g001
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infected with sterile 16PBS or infected with JEV at multiplicity of
infection (MOI) of 5. After 1K h, cells were washed twice with
sterile 16PBS to remove non-internalized virus. Three of the four
plates that were infected with JEV, were treated with SC-MO, 39
MO and 59 MO at 10 mM concentrations and all plates were
incubated for 24 h in serum free media.
After two washes with 16 PBS, cells were first fixed with BD
cytofix solution (BD Biosciences) for 15 min and permeabilized by
resuspending in permeabilization buffer (BD Cytoperm plus; BD
Biosciences) and incubated at 25uC for at least 10 min. Cells were
then washed twice in wash buffer (PBS containing 1% bovine
serum albumin) then resuspended in wash buffer at 16106 cells
per 100 mL. Primary antibody (JEV Nakayama strain; Chemicon,
USA) were added in 1:100 dilutions and incubated for 30 min at
25uC. The cells were washed with wash buffer and pelleted by
centrifugation followed by incubation with FITC conjugated
secondary antibody for 30 min. After final wash with wash buffer,
cells were resuspended in 400 mL FACS buffer and analyzed on a
FACS Calibur. The percentage of population of JEV-positive cells
was calculated after gating the populations on a Dot plot using
Cell Quest Pro Software (BD Biosciences).
Statistical analysis
Statistical analysis was performed using SIGMASTAT software
(SPSS Inc., Chicago, IL, USA). Data were compared between
groups using one-way analysis of variance followed by post hoc
test. Differences upto p,0.05 were considered significant.
Results
MOs confer protection to animal from Japanese
encephalitis
MO treatment conferred significant protection to mice
following JEV infection. The survival of mice following JEV
infection was dramatically increased with treatments of both 39
and 59 MO. Approximately 90% of all the animals that were
treated with 39MO survived as compared to 75% survival of those
animals that were treated with 59MO, post infection with JEV
(Figure 2A). Infection with JEV was accompanied with distinct
symptoms and weight loss whereas treatments with both 39 and 59
MO post JEV infection, prevented animals from suffering. Not
much considerable changes in the average body weights of JEV-
infected animals treated with both 39 and 59 MO were observed
when compared to animals belonging to JEV and JEV+ SC-MO
groups showing significant reductions in their body weights 6 days
post infection (Figure 2B). The symptoms associated with JE in
murine model were observed on daily basis and scores were
attributed accordingly. The animals that had most symptoms
received the highest scores. It was observed that 39 and 59 MO
treated animals scored lesser than those belonging to the JEV-
infected or JEV+SC-MO groups (Figure 2C).
Reduction of viral load in vivo due to MO treatment
To assess whether the MOs has any effect on reduction of viral
load in brain, homogenized brain samples from all the treatment
groups were subjected to plaque assay as described in materials
and methods section. Number of PFU/mL of the brain
homogenate was found to be significantly higher in both JEV
and JEV+SC-MO groups when compared to Sham (p,0.001).
Viral PFUs were found to be significantly reduced following 39
MO and 59 MO treatment when compared to only JEV-infected
or JEV+SC-MO group (p,0.001) (Figure 3A).
To further validate the results obtained from the plaque assay,
immunoblot for some of the JEV-specific proteins were performed.
The expression of NS5, a non structural protein of JEV, was
significantly increased in JEV and JEV+SC-MO groups when
compared to Sham (p,0.01), but its level were found to be
significantly reduced after both 39 and 59 MO treatments when
compared to JEV-infected group (p,0.01). Similarly, E glycopro-
tein level showed significant increase in JEV-infected and
JEV+SC-MO groups when compared to Sham (p,0.01) which
were then drastically reduced following 39 and 59 MO treatments
(p,0.01) (Figure 3B–D). Immunostaining of brain sections showed
greater presence of JEV antigen in JEV-infected and JEV+SC-
MO groups, whereas 39 and 59 MO treatments resulted in lesser
presence (Figure 3E).
MOs abrogates neurodegeneration, microglial activation
and release of proinflammatory cytokines in the brain
To further characterize the inhibitory effects of MO on JEV-
induced neuronal death, brain sections from all the treatment
groups were subjected to thionin staining. Numerous healthy cells
were seen in sections obtained from Sham, JEV+39 MO and
JEV+59 MO groups when compared to sections belonging to only
JEV-infected or JEV+SC-MO groups which contained numerous
unhealthy/dying neurons with altered morphology (Figure 4A).
Microglial activation and increased proinflammatory cytokine
production are the hallmarks of JEV infection [24]. To see whether
MO treatment helps in vitiation of these effects, immunostaining for
microglial specific marker Iba-1 was performed in brain sections of
all treatment groups. In brain sections of JEV and JEV+SC-MO
groups the number of activated microglia with characteristic
morphology, appeared to be more frequent when compared to
sections belonging to Sham, JEV+39 MO and JEV+59 MO groups
(Figure 4B). CBA performed to check the proinflammatory cytokines
levels in the brain homogenates obtained from different treatments
showed that levels of MCP-1, IFN-c, TNF-a, and IL-6 were found
to be significantly increased in both JEV and JEV+SC-MO groups
when compared to Sham infected groups (p,0.01). The elevated
levels of these proinflammatory cytokines were drastically reduced
with 39 and 59 MO treatments (p,0.01) (Figure 4C–F).
Modulations of oxidative stress in brain following MO
treatment
Increased oxidative stress in CNS is a major outcome of JEV
infection [20]. To evaluate whether MO treatment of mice
resulted in abrogation of oxidative stress following JEV infection,
we measured ROS and NO levels in brain homogenate obtained
from all treatment groups. Two fold increases were observed in the
ROS levels in the brain samples of JEV and JEV+SC-MO groups
when compared to Sham (p,0.01), significant reduction in the
ROS levels were observed in JEV+39 MO and JEV+59 MO
groups when compared to only JEV-infected groups (p,0.01).
Although ROS levels has decreased in JEV+39 MO group when
compared to JEV group, it remained significantly higher than that
of Sham (p,0.01) (Figure 5A). Superoxide dismutase 1 (SOD-1)
and Thioredoxin (TRX-1) are the proteins associated with
oxidative stress. SOD-1 levels were found to be elevated
approximately 2- and 3-fold in JEV-infected and JEV+SC-MO
groups respectively when compared to Sham (p,0.01). Its levels in
JEV+39 MO and JEV+59 MO groups were reduced significantly
when compared to JEV-infected group (p,0.01). TRX-1 levels
were also found to be increased significantly in JEV-infected and
JEV+SC-MO groups when compared to Sham (p,0.01) but it
were significantly reduced in brain samples obtained from JEV+39
MO and JEV+59 MO groups when compared to only JEV-
infected groups (p,0.01) (Figure 5B, D&E). HSP-70 is a heat shock
Vivo-Morpholino in Japanese Encephalitis
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protein that has been associated with intracellular stress.
Significant twelve fold increases in the levels of HSP-70 were
observed in JEV and JEV+SC-MO groups when compared to
Sham (p,0.01), this drastic increases in the levels of HSP-70 in
JEV and JEV+SC-MO groups were reduced in JEV+39 MO and
JEV+59 MO groups (p,0.01) (Figure 5B&C).
JEV infection leads to increased nitric oxide (NO) production in
CNS [25]. Significant two fold increases were seen in the NO
levels in brain samples obtained from JEV-infected and JEV+SC-
MO groups when compared to those obtained from Sham
(p,0.01). NO levels subsequently got down to significantly lower
levels following 39 and 59MO treatments (p,0.01) (Figure 5F).
Immunoblot analysis showed nearly 8-fold increases in levels of
iNOS in JEV-infected and JEV+SC-MO groups when compared
to Sham (p,0.01). iNOS levels showed significant decreases in
JEV+39 MO and JEV+59 MO groups when compared to only
JEV-infected groups (p,0.01) (Figure 5G&H).
MO treatment modulates the expression pattern of key
proteins associated with stress
Western blot analysis demonstrated a significant inhibition in the
expression of different stress related proteins whose levels were
elevated following JEV infection. Upon MO treatments there were
approximately 4-fold increases in the levels of pNFkB in JEV and
Figure 2. Mice are protected from JEV following MO treatment. The survival of mice following JEV infection was dramatically increased with
treatments of both 39 and 59 MO, though the survival in 39 MO treated mice was greater (,90%) than those treated with 59MO (75%) (A).
Considerable changes in the average body weights of JEV-infected animals treated with both 39 and 59 MO were not observed when compared to
animals belonging to JEV and JEV+ SC-MO groups that showed significant reductions in their body weights from 6th day post infection till their death.
Black arrows points to the days by which all the animals died. (B). Infection with JEV was accompanied with distinct symptoms that were alleviated
following treatments with both 39 and 59 MO. Animals were assigned scores according to the symptoms, in a blinded manner. The graph was plotted
by taking the scores of one animal that was considered as the representative of that group (C). n = 8 for all experiments; data shown are
representative of duplicate sets of experiments.
doi:10.1371/journal.pntd.0000892.g002
Figure 3. MOs treatment reduces the viral load in vivo. Significant reduction in viral titer was observed following MO treatment in animals, as
compared to JEV-infected and JEV+SC-MO groups. (* p,0.001 for JEV and JEV+SC-MO when compared to Sham, # p,0.001 for JEV+ 39MO and JEV+
59 MO when compared to only JEV-infected group) (A). Immunoblot analysis showed expression of JEV NS5 and E glycoprotein were significantly
increased in JEV-infected and JEV+SC-MO than Sham, but reduced significantly after both 39 and 59 MO treatments (* p,0.01 for JEV and JEV+SC-MO
when compared to Sham, # p,0.01 for JEV+ 39MO and JEV+ 59 MO when compared to only JEV-infected group) (B–D). Immunostaining of brain
sections from different treatment groups showed greater presence of JEV antigen in JEV and JEV+SC-MO groups (E). Magnification620; scale bar
correspond to 50m Photomicrographs shown here in this figure are representative of three individual animals from each group.
doi:10.1371/journal.pntd.0000892.g003
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JEV+SC-MO groups when compared to Sham (p,0.01). The levels
of pNFkB were found to be significantly reduced in JEV+39MOand
JEV+59 MO groups when compared to only JEV-infected groups
(p,0.01) (Figure 6A&B). Phospho p38 MAPK levels also showed
significant 3-fold increases in JEV and JEV+SC-MO groups when
compared to Sham (p,0.01), its levels were also found to be reduced
significantly following treatment with 39 and 59MOwhen compared
to only JEV-infected groups (p,0.01) (Figure 6A&C). Both phospho
ERK1 and ERK2 levels were found to be significantly increased in
JEV and JEV+SC-MO groups when compared to Sham (p,0.01).
The levels of phospho ERK1 and ERK2 showed considerable
decreases in JEV+39MO and JEV+59MO groups when compared
to only JEV-infected groups (p,0.01) (Figure 6A&D).
MO treatment reduced viral titer in vitro and decreased
the intracellular viral load
To assess whether MO has any effect on viral load in vitro N2a
cell lysates from all the treatment groups were subjected to plaque
assay. PFU/mL of the cell lysates was found to be significantly
higher in both JEV and JEV+SC-MO groups when compared to
mock-infected cells (p,0.01). Viral loads were found to signifi-
cantly reduced in both JEV+39 MO and JEV+59 MO groups
when compared to only JEV-infected group (p,0.01) (Figure S1A).
To further ascertain the results obtained from plaque assay,
intracellular staining of JEV antigen in N2a was performed and
number of JEV-positive N2a cells was then counted by flow
cytometry. Only 16% and 9% of the total gated cells were found to
be positive for JEV antigen in JEV+39 MO and JEV+59 MO
groups respectively as compared to 30% in JEV-infected group,
and 34% in JEV+SC-MO group (Figure S1B).
Discussion
Use of anti-sense molecules for targeted inhibition of viral
replication has been under investigation for quite sometime.
Though the application of these molecules has raised the
possibilities of their future use as novel therapeutic agents, there
Figure 4. MOs neuroprotect, reduces microglial activation and inhibits proinflammatory cytokines production in brain. Thionin
staining of brain sections from all the treatment groups showed neurons with distinct morphology in Sham-treated, JEV+39 MO and JEV+59 MO
groups. However in sections from JEV-infected and JEV+SC-MO groups showed damaged neurons with altered morphology. Magnification620; scale
bar correspond to 50 m. Immunofluorescent staining for microglia-specific Iba-1 performed in brain sections of all groups showed that number of
activated (star shaped) microglia appeared to be more frequent in JEV-infected and JEV+SC-MO groups as compared to compared to sections
belonging to Sham, JEV+39 MO and JEV+59 MO groups. Magnification620; scale bar correspond to 50 m (B). Photomicrographs shown here in this
figure are representative of three individual animals from each group. CBA showed levels of MCP-1, IFN-c, TNF-a, and IL-6 were increased significantly
in both JEV-infected and JEV+SC-MO groups when compared to Sham treated groups. The elevated levels of these proinflammatory cytokines were
then significantly reduced with 39 and 59 MO treatments (* p,0.01 for JEV and JEV+SC-MO when compared to Sham; # p,0.01 for JEV+ 39MO and
JEV+ 59 MO when compared to only JEV-infected group) (C–F).
doi:10.1371/journal.pntd.0000892.g004
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are many issues regarding their effectiveness in terms of their
stability and delivery to targeted cells. Recent studies are involved
in developing techniques to minimize or eliminate these issues so
that anti-sense therapy can be employed to a wide variety of
intractable diseases such as splice-modifying genetic defects and
viral diseases. The role of various anti-sense molecules in the
inhibition of replication of JEV has been reported with positive
outcomes [10,11,12,13,26].
Morpholino oligomers are single stranded anti-sense molecules
that exert their action by steric blocking of complementary RNA.
Unlike other types of anti-sense oligonucleotides, Morpholinos
provide all the desired properties of stability, nuclease resistance,
high efficacy, long-term activity, water solubility, low toxicity, and
exquisite specificity. Morpholino oligomers has been used
previously for the inhibition of flaviviral replication [14,27]
including JEV [15] though all of them has utilized peptide based
Morpholinos. The peptide based Morpholinos contain delivery
moiety evolved from natural peptides whose active components
are 6–9 arginine residues in a bio-available 6-aminohexanoic-
spaced structure [28]. However, these arginine-based peptides are
not commercially available for research purposes and their
greatest efficacies have been in delivering Morpholinos to the
cytosol of tissues like liver [29] or leaky muscle [30], which would
be considered as easily deliverable. As a result, the reach of peptide
based Morpholinos into a wide spectrum of tissues remains
questionable [18]. Also, owing to the peptidic nature, degradation
of the peptide portion of the conjugates was found to be time and
tissue dependent [31]. Furthermore, the applications of the
arginine-rich peptide transporters are limited due to their high
cost, scalability and stability. Added to that are the risks of immune
responses against the peptides which limits repeated administra-
tions for diseases requiring long-term treatment [32].
Figure 5. MOs treatment modulates oxidative stress markers in CNS. Increases were observed in the ROS levels in the brain samples of JEV-
infected and JEV+SC-MO groups in comparison to Sham, that were reduced following 39 and 59 MO treatments. Although ROS levels were decreased
in JEV+39 MO group when compared to JEV-infected group, it remained significantly higher than that in Sham (A). Approximately 13-fold increases
were observed in the levels of HSP-70 in JEV-infected and JEV+SC-MO groups as compared to Sham. These drastic increases were significantly
reduced in JEV+39 MO and JEV+59 MO groups, the levels remained significantly higher than Sham (B&C). SOD-1 levels were found to be elevated 2-
and nearly 3-fold in JEV-infected and JEV+SC-MO groups respectively compared to Sham. 39 and 59 MO treatment caused significant reduction of
SOD-1 levels compared to JEV-infected group (B&D). Alterations in TRX-1 levels were similar to that observed in SOD-1 except that its level in JEV+ SC-
MO was not significantly different than only JEV-infected group (B&E). Nearly 2-fold increases were observed in NO levels of JEV-infected and JEV+SC-
MO groups when compared to those obtained from Sham. NO levels were subsequently reduced to significantly lower levels following 39 and 59MO
treatments (F). iNOS expression was found to increase 8-fold in JEV-infected and JEV+SC-MO groups when compared to Sham. Following 39 and
59MO treatments iNOS levels decreased significantly as compared to JEV-infected group (G&H). (* p,0.01 for JEV when compared to Sham; ** p,0.01
for JEV+SC-MO when compared to JEV-infected only; # p,0.01 for JEV+ 39MO and JEV+ 59 MO when compared to only JEV-infected group;ˆ p,0.01
for JEV+ 39MO when compared to Sham; $ p,0.01 for JEV+ 59 MO when compared to Sham).
doi:10.1371/journal.pntd.0000892.g005
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To minimize the problems encountered by the peptide-
conjugated Morpholinos, octaguanidinium dendrimer-conjugated
Morpholino oligomers have been developed that are commonly
referred to as Vivo-Morpholino (MO). These custom-sequence
anti-sense molecules have been reported to enable Morpholino
applications in adult animals. MO was our choice of anti-sense
molecule as this enabled us to test the specifically designed
oligonucleotides in both animal as well as cell culture models.
Though ‘outstanding’ results have been reported to be achieved by
intravenous (i.v.) administration of the MO, we preferred the
intraperitoneal route via which modest systemic delivery can be
achieved. This was so done because brain has been reported to be
an ineffective tissue when MOs are administered i.v. [33], though
there is no direct evidence showing that MOs can cross blood
brain barrier, when administered via other routes. According to
the manufacturer’s (Gene Tools LLC) instructions the maximum
suggested dosage in mammals is 12.5 mg/kg in a 24 hour period.
Our aim was to determine the minimum dose at which our desired
effects could be achieved. Initially we had chosen two doses of
5 mg and 10 mg per kg body weight (b.w.) of the animals. We
found that there was no significant difference between the survival
rate of JEV-infected and MO treated mice in either dose (data not
shown for 10 mg/kg b.w.). The survival rate was approximately 90%
in those JEV-infected animals that were treated with 39 MO and
75% in animals treated with 59 MO. Thus we decided to proceed
with the 5 mg/kg b.w. dose for all subsequent experiments.
Plaque assay from the brain homogenates of animals of all
groups revealed that the number of infective viral particle
production was dramatically reduced following 39 and 59 MO
treatment. The 39MO was generated against the 39 CSI region of
the JEV genome that interacts with 59 CS region located in coding
sequence for capsid protein at 136–146 nucleotides from 59
terminal of the genome. This interaction results in cyclization of
JEV genome that is necessary for its efficient replication. The 59
MO was targeted towards one of the secondary structures of the 59
UTR that are required for the formation of translation pre-
initiation complex. Blocking of these two sites in the JEV genome
leads to the most likely effect, i.e. inhibition of replication and
translation of viral genome. This was further corroborated by the
decrease in the expressions of viral proteins (NS5, E glycoprotein
Figure 6. MOs regulates the expression pattern of several key proteins associated with stress. Approximately 4-fold increases in the
levels of pNFkB and 3-fold increases in the levels of phosphoP38MAPK in JEV-infected and JEV+SC-MO groups were observed in comparison to Sham.
The levels of both pNFkB and phosphoP38MAPK were significantly reduced in JEV+39 MO and JEV+59 MO groups when compared to only JEV-
infected groups (A–C). Phospho ERK1 and ERK2 levels were found to be increased by approximately 3- and 5-fold in JEV-infected and JEV+SC-MO
groups respectively, when compared to Sham. but showed considerable decreases in JEV+39MO and JEV+59 MO groups when compared to only JEV-
infected groups (A&D) (* p,0.01 for JEV-infected and JEV+SC-MO when compared to Sham; # p,0.01 for JEV+39 MO and JEV+59MO when compared
to only JEV-infected groups).
doi:10.1371/journal.pntd.0000892.g006
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and general flaviviral envelop protein) in the brain. Flaviviral NS5
is known to possess guanylyltransferase activity that helps in the
synthesis of methylated cap structure at the 59 end of the viral
genome that plays a crucial role in the translation and stability of
mRNAs [34]. The JEV E glycoprotein is believed to be involved in
viral adhesion and entry into host cells, hemagglutination, cellular
tropism, viral virulence, and the induction of protective immune
responses [35]. Decreased expression of these proteins indicates
that viral replication and production of new infective viral particles
are inhibited due to the MOs. Immunohistochemical staining for
viral antigen also provided visual confirmation of the fact that JEV
antigen was detected at much lower amounts in the brain
following MO treatment. However, these data does not prove that
MOs directly inhibit infective viral particle production in the brain
itself, as it cannot be conclusively stated whether the MOs can
reach brain. These data merely suggests that the number of
replication-competent infective JEV in the brain was significantly
reduced, which subsequently leads to neuroprotection.
It is well known that JEV infection causes microglial activation.
Activated microglia releases an array of chemical mediators that
are detrimental for the neurons in brain [24]. Since there was
reduction in the production of infective viral particles following 39
and 59 MO treatments, we studied the effect on microglial
pathophysiology in mouse brain. Our results show that there was
significantly reduced number of activated microglia in the brain
sections of both 39 and 59 MO-treated animals as compared to
only JEV-infected or JEV-infected and SC-MO treated animals.
Since there were little or no activation of microglia, proinflamma-
tory cytokine levels in the brain were found to be significantly
downregulated. Histochemical staining also revealed that neuronal
population and morphology remained largely unaffected in 39 and
59 MO-treated animals’ brains as compared to only JEV-infected
or JEV-infected and SC-MO treated animals.
Generation of ROS with the generation of oxidative damage
has been implicated in neurodegenerative diseases and in the
degradation of nervous system functions and are also reported to
increase following JEV infection [22]. Increase in ROS levels
initiates various responses within the cell, including damage to
proteins, DNA and lipid [36]. In this study, ROS levels were found
to be many-fold increased in JEV-infected or JEV-infected and
SC-MO treated animals that were then found to be counteracted
by the treatment of 39 and 59 MO. The levels of stress related
proteins such as SOD-1, HSP-70 and TRX where also found to be
positively modulated following 39 and 59 MO treatment. NO is a
known antagonist of JEV. It has been shown that NO inhibits JEV
infection by preventing viral replication [37]. In our study NO
levels were increased in the brain in response to JEV infection
possibly due to the upregulation of inducible nitric oxide synthase
(iNOS). Treatments with 39 and 59 MO caused a decrease of NO
to basal levels as observed in Sham-treated animals.
Activation of pNFkB regulates apoptotic genes, especially the
TRAF1 and TRAF2, and thereby checks the activities of the
caspases, which are central to most apoptotic processes. JEV is
known to activate pNFkb via a PI3K-dependent pathway in the
brain of infected animals, which is associated with apoptosis [38].
JEV infection has also been shown to activate stress kinases, which
in turn results in activation of ERK1/2, and p38 MAPK pathway
leading to apoptotic death of neurons [39]. In accordance with the
established results, here also we found that there was similar
activation pattern of these molecules in JEV-infected and JEV-
infected and SC-MO treated animal brain samples. Treatment
with the MOs resulted in abrogation of those changes that led to
greater survivality of brain neurons as observed by histochemical
staining. Activation of p38MAPK is also related to the
transcriptional activation of proinflammatory genes in the brain
[40]. Thus the decrease in phophoP38 MAPK levels correlates
with the decreased levels of proinflammatory cytokine levels in
obtained from the brain.
To confirm the anti-viral and neuroprotective property of the
MOs observed in in vivo models, cultured neuroblastoma cells were
infected with JEV, followed by MO treatment. Though the MOs
are specifically developed for in vivo studies, they are also known to
be taken up by cells in culture conditions [18]. There was a
significant decrease in viral titer in samples obtained from the cells
that were treated with 39 and 59 MOs as compared to either JEV-
infected or JEV-infected and SC-MO treated cells, as revealed by
plaque assay. This data was supported by FACS analysis following
intracellular staining for JEV antigen.
This study was undertaken to determine the antiviral and
neuroprotective efficacy of Vivo-Morpholinos in an experimental
model of JE so that it can be considered as a therapeutic agent in
the near future. There have been studies regarding the anti-JEV
effects of other types of Morpholino oligomers though none of
them are yet to be considered for therapeutic purposes. This is the
first study that investigates the role of Morpholino oligomers
specially designed for effective delivery into live animal models.
Generally, the i.p route of administration of any drug is preferred
in animal studies over any other routes. However, the efficacy of
these antisense molecules needs to be checked by administering
through other applicable routes, as i.p. administration in humans
is uncommon, though not unheard of. The amounts of oligomers
required and the route of administration in this study marks these
molecules as practicable therapeutic agents in JE, though further
studies are required before these can be recommended for clinical
trials.
Supporting Information
Figure S1 MO treatments decrease viral load in vitro. Mouse
neuroblastoma cell (N2a) lysates from all the treatment groups
were subjected to plaque assay in order to determine viral loads.
PFU/mL was found to be significantly higher in both JEV and
JEV+SC-MO groups when compared to Sham. Viral loads were
found to be significantly reduced in both JEV+39MO and JEV+59
MO groups when compared to only JEV-infected group (* p ,
0.01 for JEV and JEV+SC-MO when compared to Sham; # p ,
0.01 for JEV+39 MO and JEV+59MO when compared to only
JEV-infected group) (A). Intracellular staining for JEV antigen in
N2a was performed and number of JEV-positive N2a cells was
then sorted by flow cytometry. 30% of the total gated cells were
found to be positive for JEV antigen in JEV-infected group as
compared to 34% in JEV+SC-MO group. Only 16% and 9% of
the total gated cells were found to be positive for JEV antigen in
JEV+39 MO and JEV+59 MO groups respectively (B).
Found at: doi:10.1371/journal.pntd.0000892.s001 (0.25 MB TIF)
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